Pharvaris N.V. (PHVS) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 495.3% versus a gain of 41.2%. Over five years, PHVS leads with a +100.5% price change compared with +28.1% for SLS. SELLAS Life Sciences Group is the larger company by market cap ($2.28 billion vs $2.22 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | SLS |
|---|---|---|
| Share price | $31.68 | $11.31 |
| Market cap | $2.22B | $2.28B |
| 1-day change | +1.80% | -0.26% |
| YTD return | +14.16% | +200.00% |
| 1-year return | +41.18% | +495.26% |
| 5-year return | +100.51% | +28.09% |
| EPS (TTM) | $-3.06 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.25 | $15.88 |
| 52-week low | $20.65 | $1.39 |
| Distance from 52-week high | -26.75% | -28.78% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +80.62% | +187.36% |
| Average volume | 740.93K | 6.75M |
| Shares outstanding | 70.20M | 201.95M |
| Employees | 148 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed PHVS by 454.1 percentage points over the past year.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
PHVS vs SLS FAQ
Which is bigger, Pharvaris N.V. or SELLAS Life Sciences Group?
SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.28B compared with $2.22B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, PHVS or SLS?
SLS returned +495.26% over the past 12 months, compared with +41.18% for PHVS (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.